

2 STUDY SYNOPSIS

Name of Company: Eisai Inc.	INDIVIDUAL STUDY TABLE	(For National Authority Use Only)
Name of Finished Product: Lenvatinib hard capsules	Referring to Module 5 of the Dossier	
Name of Active Ingredient: Lenvatinib (E7080)	Volume: Page:	

Study Title

An Open-Label, Multicenter Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Investigators/Sites

Phase 2: A total of 37 sites in 5 countries (Czech Republic [5 sites], Poland [4 sites], Spain [4 sites], the United Kingdom [11 sites], and the United States [13 sites]).

Publication (Reference)

Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). *Cancer Chemother Pharmacol* 2014;73:181–189.

Motzer R, Hutson T, Glen H, Michaelson D, Molina A, Eisen A, et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). Presentation at the 2015 ASCO Annual Meeting. Chicago (IL) *J Clin Oncol* 33, 2015 (suppl; abstr 4506).

Study Period

Phase 2: 16 Mar 2012 (first subject provided informed consent) to 13 Jun 2014 (data cutoff date for the primary endpoint)

Phase of Development

Phase 1b/2 (The Phase 2 part of the study is reported in this clinical study report [CSR])

Objectives (Phase 2)

Primary

- To compare the progression-free survival (PFS) of 1) lenvatinib in combination with everolimus at the recommended Phase 2 (RP2) dose once daily (QD) (Arm A) and 2) single agent lenvatinib 24 mg QD (Arm B) to single agent everolimus 10 mg QD (Arm C) in subjects with unresectable advanced or metastatic renal cell carcinoma (RCC) and disease progression following 1 prior vascular endothelial growth factor (VEGF)-targeted treatment.

Secondary

- To determine the tolerability and safety profile of lenvatinib in combination with everolimus and of single agent lenvatinib.
- To compare PFS of Arm A, lenvatinib-everolimus combination therapy to Arm B, single agent lenvatinib.
- To assess overall survival (OS).
- To assess objective response rate (ORR: complete response + partial response [CR + PR]); disease control rate (DCR: CR + PR + stable disease [SD]); durable SD (SD ≥ 23 weeks) and clinical benefit rate (CBR: CR, PR + durable SD rate).
- To assess pharmacokinetic (PK) profiles (eg, AUC, C_{max}) of lenvatinib and everolimus during single agent and combination therapy.
- To assess PK and pharmacodynamic (PD) relationship of lenvatinib as single agent and combination therapy.

Exploratory

- To identify and explore blood and tumor biomarkers which correlate with efficacy-related endpoints of this study.
- To evaluate role of DNA sequence variability on absorption, distribution, metabolism, excretion (ADME) and susceptibility to adverse events (AEs) of lenvatinib.

Methodology

This was a multicenter, open-label, Phase 1b/2 study of lenvatinib administered alone and in combination with everolimus in subjects with unresectable advanced or metastatic RCC. The study consisted of 2 parts: Phase 1b and Phase 2. The Phase 2 part of the study is reported in this CSR; Phase 1b is reported separately.

Phase 2 included a Prerandomization Phase, a Randomization Phase, and an Extension Phase. Subjects were randomized into 3 arms to receive: 1) 18 mg/day lenvatinib + 5 mg/day everolimus (RP2 dose; Arm A [combination arm]), 2) lenvatinib 24 mg/day (Arm B [lenvatinib arm]), or 3) everolimus 10 mg/day (Arm C [everolimus arm]). Randomization was stratified by hemoglobin (≤ 13 g/dL vs > 13 g/dL for males and ≤ 11.5 g/dL vs > 11.5 g/dL for females) and corrected serum calcium levels (≥ 10 mg/dL vs < 10 mg/dL).

Number of Subjects (Planned and Enrolled)

Planned: Approximately 150 subjects were planned to be enrolled in Phase 2 part of the study.

Enrolled: A total of 153 subjects were enrolled.

Diagnosis and Main Criteria for Inclusion

Eligible subjects had unresectable or advanced RCC, histological or cytological confirmation of predominant clear cell RCC, radiographic evidence of disease progression on or within 9 months of stopping prior therapy, 1 prior VEGF-targeted therapy, and measurable disease according to RECIST 1.1. Other key eligibility criteria included Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤ 1 , adequately controlled blood pressure with or without antihypertensive medications, and adequate renal, bone marrow, blood coagulation, liver, and cardiac function.

Test Treatment, Dose, Mode of Administration, and Batch Numbers

Lenvatinib was provided as 1-mg, 4-mg and 10-mg capsules. Everolimus was provided as 5-mg tablets. Lenvatinib capsules and everolimus tablets were to be self-administered orally by the subjects preferably in the morning (consistently either with or without food) in continuous 28-day cycles as follows:

- Arm A (combination arm): the RP2 dose of Lenvatinib (18 mg) QD + everolimus (5 mg) QD
- Arm B (lenvatinib arm): Lenvatinib 24 mg QD

Dose interruption, dose reduction, or treatment discontinuation was allowed for subjects who experienced lenvatinib-related toxicity. Subjects in the combination arm who experienced everolimus-related toxicity had dose adjustments in accordance with prescribing information.

Lenvatinib Batch/Lot Nos.:	1-mg capsules:	P9X007ZZA, P92016ZZB
	4-mg capsules:	P16004ZZA, P9X008ZZA, P9X009ZZB, P09012ZZA, P1X042ZZA, P93012ZZB
	10-mg capsules:	P9X010ZZB, P9X012ZZA, P14017ZZA, P14018ZZA, P1Y014ZZA, P22012ZZA, P93014ZZC

Reference Therapy, Dose, Mode of Administration, and Batch Numbers

Everolimus was provided as 5-mg tablets. In Arm C (everolimus arm), everolimus 10 mg QD was to be self-administered orally by the subjects in the morning (consistently either with or without food) in continuous 28-day cycles. Subjects who experienced everolimus-related toxicity had dose adjustments in accordance with prescribing information.

Everolimus Batch/Lot Nos.: 5-mg tablets: F0003, F0006, F0008, F0011, F0012, S0013A, S0021

Duration of Treatment

Subjects received study treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.

Assessments**Efficacy**

Tumor assessments using RECIST 1.1 were performed during the Prerandomization Phase and then every 8 weeks (or sooner if there was evidence of progressive disease) from the date of randomization in the Randomization Phase, and in the Extension Phase. Tumor assessments were performed until documentation of disease progression. Subjects who discontinued the study treatment without disease progression in the Randomization Phase had to undergo tumor assessments every 8 weeks in the Randomization Phase, until disease progression was documented or another anticancer therapy was initiated. During the Extension Phase, subjects who discontinued study treatment without disease progression had tumor assessments performed as clinically indicated using the investigator's discretion, following the standard of care at their institution.

Investigator-determined response assessments were performed at each assessment time point.

Pharmacokinetic Assessments

Blood samples for determination of plasma concentrations of lenvatinib and blood concentrations of everolimus were collected at protocol-specified time points from all subjects during the Randomization Phase. Most subjects had 6 samples taken over 3 cycles of treatment (ie, sparse sampling). However, between 9 and 12 subjects in each of the 3 treatment arms in Phase 2 participated in an optional substudy where instead of the sparse sampling, intensive sampling was performed (ie, full PK profiling).

Safety

Safety was assessed by the monitoring and recording of all AEs and serious AEs (SAEs); regular monitoring of hematology, clinical chemistry, and urine values; and regular measurement of vital signs, electrocardiograms (ECGs), and Multiple Gated Acquisition (MUGA) scans.

Bioanalytical Methods

Lenvatinib in plasma and everolimus in blood were quantified using validated high performance liquid chromatography-tandem mass spectroscopy methods.

Statistical Methods**Primary Efficacy Endpoint**

- Progression-free survival defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first) as determined by the investigator using RECIST 1.1.

Secondary Efficacy Endpoints

- Overall survival measured from the date of randomization until date of death from any cause.
- Objective response rate defined as the proportion of subjects who had best overall response (BOR) of CR or PR as determined by the investigator using RECIST 1.1.
- Disease control rate defined as the proportion of subjects who had BOR of CR or PR or SD (minimum duration from randomization to SD ≥ 7 weeks).
- Clinical benefit rate defined as the proportion of subjects who had BOR of CR or PR or durable SD (duration of SD ≥ 23 weeks).
- Durable SD rate defined as the proportion of subjects with duration of SD ≥ 23 weeks.

Analysis Sets

- Full Analysis Set (FAS) included all subjects randomly assigned to treatment. This was the primary analysis set for efficacy endpoints.
- Phase 2 PK Sub Analysis Set consisted of subjects who participated in the intensive PK sampling portion of Phase 2 of the study.
- Safety Analysis Set included all subjects who received at least 1 dose of the study drug and had at least 1 postbaseline safety evaluation. This was the analysis set for all safety evaluations.

Sample Size Determination and Statistical Methods

The planned sample size for the primary analysis required a total of at least 90 PFS events to be observed across all 3 treatment groups, and at least 60 PFS events to be observed for each of the comparisons of the combination versus the everolimus arm, and the lenvatinib versus the everolimus arm. The assumed median PFS for everolimus 10 mg was 5 months based on historical data. Given that there were no prior clinical data available for the combination of lenvatinib plus everolimus, and limited data for lenvatinib alone in the target population, it was appropriate to consider that a HR=0.67 represents a clinically meaningful improvement in PFS. Under the assumption of an exponential event distribution of the time to PFS random variable, this effect translated into median PFS of 7.5 months. The study was designed as a Phase 2 study where a total of 90 PFS events were required to detect a HR of 0.67 with 70% power using an (1-sided) alpha of 0.15 for the comparison of the combination arm (and lenvatinib arm) versus the everolimus arm. An independent statistical review was conducted to ensure that at least 60 PFS events were observed for each of the comparisons of the combination versus the everolimus arm, and the lenvatinib versus the everolimus arm. The actual observed number of PFS events was to be used to calculate the hazard ratio when comparing treatment arms.

Efficacy Analyses

All efficacy analyses were based on investigator assessment on the FAS. Primary comparison of PFS was between combination arm and everolimus arm or lenvatinib arm and everolimus arm. Secondary comparison of PFS was between combination arm and lenvatinib arm. There was no prespecified ordering in testing these hypotheses (primary and secondary) and each null hypothesis was tested at a nominal $\alpha=0.05$.

For each treatment comparison (combination arm vs everolimus arm or lenvatinib arm vs everolimus arm), null hypothesis of no difference in PFS was analyzed using the stratified log-rank test with hemoglobin (≤ 13 g/dL vs >13 g/dL for males; and ≤ 11.5 g/dL vs >11.5 g/dL for females) and corrected serum calcium (≥ 10 mg/dL vs <10 mg/dL) as stratification factors. Median PFS was estimated using the Kaplan-Meier (K-M) product-limit estimates for each arm and the corresponding 2-sided 95% confidence interval (CI) was computed using the Greenwood formula. Hazard ratio (HR) between treatment groups and corresponding 95% CI was estimated using the stratified Cox regression model (stratified by hemoglobin and corrected serum calcium) with treatment as a factor.

Secondary efficacy endpoints: OS analyses were performed using the stratified Cox proportional model used for the primary analysis. Each null hypothesis of no difference in OS was evaluated using the stratified log-rank test, and tested at (2-sided) $\alpha=0.05$. Median OS and its corresponding (2-sided) 95% CI were estimated similarly as for the primary analysis for PFS. ORR, DCR, CBR and durable SD rate were calculated with exact 95% CIs using the method of Clopper and Pearson. Ad-hoc analyses were performed to estimate the crude rate ratio of each treatment comparison and to compute *P* values using the Fisher's exact (2-sided) test.

Pharmacokinetic Analyses

Population PK model analysis was performed with sparse sampling PK using data from other lenvatinib studies as appropriate for the population PK model. The population PK analysis and PK/PD results are reported separately.

For the intensive PK sampling substudy, PK parameters were derived using non-compartmental methods for lenvatinib and everolimus during single agent and combination therapy. To assess any drug-drug interaction between lenvatinib and everolimus, the primary PK parameters of lenvatinib and also everolimus from the Phase 2 PK data set were compared graphically and via descriptive statistics between single agent and combined therapy.

Safety Analyses

Safety data were summarized using descriptive statistics. Categorical variables were summarized by number and percentage. Continuous variables were summarized using *n* (number of subjects with available data), mean, standard deviation (SD), median, and range (minimum and maximum) unless otherwise specified. ECG findings and the incidence of AEs and SAEs were summarized. Laboratory test results, vital signs, and left ventricular ejection fractions (from MUGA Scans), and their changes from baseline, were summarized using descriptive statistics.

Results

Subject Disposition/Analysis Sets

In total, 153 subjects were randomly assigned to the 3 treatment arms: 51 subjects to the combination arm, 52 subjects to the lenvatinib arm, and 50 subjects to the everolimus arm. Mean and median age were well balanced

among the treatment arms. The treatment arms also were well balanced across parameters, including the independent prognostic factors in RCC: ECOG PS, corrected serum calcium (stratification factor), and hemoglobin level (stratification factor). All 153 subjects were treated. Data cutoff occurred as planned on 13 Jun 2014 following the occurrence of 101 PFS events among the 3 treatment arms, 63 PFS events in the combination versus everolimus arm, and 75 PFS events in the lenvatinib versus everolimus arm.

At the time of data cutoff, a higher number of subjects in the combination arm (13; 25.5%) were still on treatment than in the lenvatinib or everolimus arms (7; 13.5% and 3; 6.0%, respectively). Fewer subjects ended treatment due to disease progression in the combination arm (19; 37.3%) and lenvatinib arms (29; 55.8%) than in the everolimus arm (35; 70.0%).

As of the date of data cutoff, 69 (45.0%) subjects (31 in the combination arm, 23 in the lenvatinib arm, and 15 in the everolimus arm) remained in the study, including 23 (15.0%) subjects who were still receiving study treatment.

All 153 subjects who were randomized and treated were included in the FAS and the Safety Analysis Set.

Efficacy

- In patients with mRCC and disease progression following 1 prior VEGF-targeted treatment, the combination of lenvatinib 18 mg with everolimus 5 mg demonstrated statistically significant and clinically meaningful improvement in PFS compared with the everolimus arm (median 14.6 months vs 5.5 months, respectively).
- The combination showed improvement in PFS over everolimus for all subgroups analyzed (HRs range from 0.14 to 0.61).
- The combination arm showed an impressive, statistically significant ($P < 0.0001$) and clinically meaningful improvement in ORR (43.1%) compared with both single agent arms (26.9% for the lenvatinib arm, and 6.0% for the everolimus arm).
- The combination arm showed a trend toward prolonged survival ($HR = 0.55$) compared with the everolimus arm that reached statistical significance ($P = 0.0242$) in the updated OS analysis based on a 10 Dec 2014 data cutoff ($HR = 0.51$). Median survival was 25.5 months for the combination arm and 15.4 months for the everolimus arm.
- Lenvatinib also showed a statistically significant improvement ($P = 0.0479$) in PFS (median 7.4 months) compared with everolimus.
- The ORR for the lenvatinib arm versus the everolimus arm was statistically significant ($P = 0.0067$) favoring the lenvatinib arm.

Pharmacokinetics (Phase 2 PK Sub-analyses)

- Based on the dose-normalized C_{max} and $AUC_{(0-24)}$, the mean lenvatinib C_{max} was similar between the combination and the lenvatinib arms while the mean systemic exposure as measured by $AUC_{(0-24)}$ was approximately 20% lower in the combination arm compared to the lenvatinib arm.
- Based on the dose-normalized C_{max} and $AUC_{(0-24)}$, the mean everolimus C_{max} was approximately 30% greater in the combination arm compared to the everolimus arm. A similar increase was observed with the mean $AUC_{(0-24)}$ being approximately 50% higher in the combination arm compared to the everolimus arm. These results should be viewed with caution given the small number of subjects in each treatment arm.
- In conclusion, the combination of lenvatinib and everolimus has shown substantial evidence of superior efficacy in terms of improved PFS, higher ORR and longer OS (as per the updated data) compared with standard everolimus in treatment of subjects with unresectable advanced or metastatic RCC who had progressed following 1 prior VEGF-targeted treatment.

The results of the population PK and PK/PD model are reported in a separate report.

Safety

- Subjects in the combination arm received a median of 9.0 cycles of treatment with approximately 75% of the intended dose of lenvatinib and 94% of the intended dose of everolimus, achieving longer exposure compared with subjects on the lenvatinib (median of 8.5 cycles) or everolimus (median of 5.0 cycles) arms.
- The percentage of subjects with lenvatinib dose reduction and/or dose interruption (as an action taken on the Adverse Event CRF) was similar in the combination and lenvatinib arms (84.3% and 78.8%, respectively). The percentage of subjects with study treatment discontinuation was similar in both lenvatinib containing arms (23.5% for the combination and 25.0% for the lenvatinib arm).

- The AE profile for lenvatinib was as expected for this class of compounds and consistent with the lenvatinib label and the clinical program as a whole. Similarly, the AE profile of everolimus was consistent with its label.
- Diarrhea (84%) was the most frequently reported TEAEs overall across the 3 treatment arms (>30% of subjects in any treatment arm) and occurred most often in the combination arm. Other common TEAEs in the combination arm included decreased appetite (51%), fatigue (47%), vomiting (45%), nausea (41%), hypertension (41%), cough (37%), hypertriglyceridemia (35%), hypercholesterolemia (33%), and weight decreased (31%). These events are consistent with the safety profile of lenvatinib.
- Grade 3 AEs were reported in 70.6%, 82.7%, and 52.0% subjects in the combination, lenvatinib, and everolimus arms, respectively. Substantially fewer Grade 4 events were reported in all 3 treatment arms, with similar incidence across the arms (13.7%, 9.6%, and 12.0% in the combination, lenvatinib, and everolimus arms, respectively).
- Grade 3 gastrointestinal (GI) events, including diarrhea and vomiting, occurred at a higher frequency in the combination arm (35.3%) than in the lenvatinib (19.2%) and everolimus (6.0%) arms. In addition, GI SAEs were reported more frequently in the combination (11.8%) than in the lenvatinib (3.8%) and everolimus arms (0%).
- The incidence of nonfatal (ie, other) SAEs in the combination and lenvatinib arms was similar, and was higher compared with the everolimus arm: (52.9% and 50.0% vs 42.0%, respectively).
- Serious renal events were reported with similar frequency in the combination (7.8%) and lenvatinib arms (9.6%), suggesting no increase in renal toxicity when lenvatinib was combined with everolimus.
- The occurrence of serious infections was similar among the combination (9.8%), and everolimus (10.0%) arms, as was the occurrence of serious pneumonitis (2.0% and 6.0% for the combination and everolimus arms, respectively).
- Death due to AEs occurred in 1 (2.0%) subject in the combination arm, 3 (5.8%) subjects in the lenvatinib arm, and 2 (4.0%) subjects in the everolimus arm. When adjusted by treatment duration, the incidence of fatal AEs was 0.03 episodes per subject year (SY) in the combination, 0.09 episodes per SY in the lenvatinib, and 0.08 episodes per SY in the everolimus arm.
- Diarrhea and vomiting were the most frequently reported AEs that led to dose reduction and/or interruption in the combination arm. These events resulted in dose reduction and/or interruption more often in the combination than in the lenvatinib arm: 41.2% vs 28.8%, respectively, for diarrhea and 19.6% vs 5.8%, respectively, for vomiting.
- The percentages of subjects with study treatment discontinuation due to AEs (as an action taken on the Adverse Event page of the CRF) were similar in both the combination and lenvatinib arms (23.5% and 25.0%, respectively) and were approximately 2-fold higher than in the everolimus arm (12.0%).
- The percentage of subjects who had everolimus dose interruptions due to AEs was higher in the combination arm than in the everolimus arm (76.5% vs 54.0%), while the percentage of subjects with everolimus dose reductions was higher in the everolimus arm (26.0%) than in the combination arm (2.0%). The percentage of subjects with study treatment discontinuation due to AEs (as an action taken on the Adverse Event CRF) was higher in the combination arm (23.5%) compared to everolimus arm (12.0%).
- Overall, clinically significant AEs for lenvatinib occurred in 38 subjects (74.5%) in the combination arm, 48 subjects (92.3%) in the lenvatinib arm, and 31 subjects (62.0%) in the everolimus arm, and are consistent with the known safety profile of each drug. The clinically significant AEs, especially the main characteristic toxicities of lenvatinib (hypertension and proteinuria) and everolimus (stomatitis, non-infectious pneumonitis, renal events, and infections) showed that the incidence or severity of these toxicities was not worsened when administered in combination compared to the individual/monotherapy treatments.

Conclusions

Although this study was not designed as a formal Phase 3 study, it does provide substantial evidence of the efficacy of the combination when compared to the approved comparator, everolimus. The results are statistically significant, clinically meaningful and internally consistent as demonstrated by the robust statistical superiority in all subgroups for PFS and ORR and further supported by a trend in OS that reached nominal significance in a post-hoc update analysis. The safety profile of the combination showed increase in GI (diarrhea, vomiting) events relative to the single agents. Importantly, significant AEs known to occur with each single agent did not increase above the single agent frequency or severity in the combination arm.

Date of Report

13 OCT 2015

Name of Finished Product in Germany: Kisplyx®

Name of Active Ingredient: Lenvatinib

16.1.4 List of Investigators and Other Important Participants in the Study

List of Investigators

Curriculum vitae for each of the principal investigators listed below is provided on the following pages. Even though some of the investigators did not have any subjects enrolled at their site, they are listed on the submitted 1572.

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
United States	1001	Robert J. Motzer, MD Memorial Sloan-Kettering Institute Cancer Center 1275 York Avenue New York, NY 10065	
United States	1002	Marc Dror Michaelson, MD Massachusetts General Hospital Boston, MA 02114	Enrollment in Phase 1b only.
United States	1003	Thomas E. Hutson, DO, PharmD, FACP Texas Oncology, Sammons Cancer Center 3410 Worth Street Dallas, TX 75246	
United States	1004	Ralph V. Boccia, MD Center for Cancer and Blood Disorders 6410 Rockledge Drive Bethesda, MD 20817	Site closed, no subjects enrolled
United States	1005	Edward Gelmann, MD Columbia University Medical Center 161 Fort Washington Avenue New York, NY 10032	Site closed, no subjects enrolled
United States	1006	Mayer N. Fishman, MD, PhD H. Lee Moffit Cancer Center & Research Institute 12902 Magnolia Drive Tampa, FL 33612	
United States	1007	Ali H. Moussa, MD Tulsa Cancer Institute, PLLC 12697 East 51st Street South Tulsa, OK 74101	Site closed, no subjects enrolled
United States	1008	Evan M. Hersh, MD The University of Arizona Arizona Cancer Center 1515 North Campbell Avenue P.O. Box 245024 Tucson, AZ 85724-5024	Site closed, no subjects enrolled

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
United States	1009	Birbal S. Bhaskar, MD, FACP Medical Oncology Care Associates 1010 West LaVeta Avenue, Suite 250 Orange, CA 92868	Site closed, no subjects enrolled
United States	1011	Bruce B. Bank, MD Northwest Oncology & Hematology, S.C. 820 Biesterfield Road, Suite 210 Elk Grove Village, IL 60007	Site closed, no subjects enrolled
United States	1012	Frederick R. Aronson, MD Maine Center for Cancer Medicine 100 Campus Drive, Unit 108 Scarborough, ME 04074	Site closed, no subjects enrolled
United States	1013	Fairooz F. Kabbinavar, MD UCLA Medical Hematology and Oncology 924 Westwood Blvd Los Angeles, CA 90024	
United States	1014	Pasquale W. Benedetto, MD University of Miami Hospital & Clinics 1475 North West 12 th Avenue Miami, FL 33136	Site closed, no subjects enrolled
United States	1015	Julian B. Hill, Jr., MD Hematology & Oncology Associates at Bridgeport 961 S. Gloster Street Tupelo, MS 38801	Previous PI – David G. Morris, MD
United States	1016	Harry A. Drabkin, MD Medical University of South Carolina University Hospital 171 Ashley Avenue Charleston, SC 29425	
United States	1017	Nayyar Siddique, MD Sharp Clinical Oncology Research 7901 Frost Street San Diego, CA 92123	
United States	1018	Andre Kiem D. Liem, MD Pacific Shores Medical Group 1043 Elm Avenue, Suite #104 Long Beach, CA 90813	Site closed, no subjects enrolled
United States	1019	Kulumani M. Sivarajran, MD Joliet Oncology-Hematology Associates, Ltd. 2614 West Jefferson Street Joliet, IL 60435	

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
United States	1020	Peter Julian Rosen, MD Providence Saint Joseph Medical Center Disney Family Cancer Center 181 South Buena Vista Street Burbank, CA 91505	Site closed, no subjects enrolled
United States	1022	Peter Robert Graze, MD, FACP Anne Arundel Medical Center (AAMC) 2001 Medical Parkway Annapolis, MD 21401	
United States	1023	Robert S. Alter, MD Hackensack University Medical Center 30 Prospect Avenue Hackensack, NJ 07601	
United States	1024	Asim Amin, MD, PhD Levine Cancer Institute (<i>Current</i>) 1021 Morehead Medical Drive Charlotte, NC 28204 Carolinas HealthCare System (<i>Previous</i>) Levine Cancer Institute 1025 Morehead Medical Drive, Suite 600 Charlotte, NC 28204	
United States	1026	David H. Irwin, MD Alta Bates Summit Comprehensive Cancer Center 2001 Dwight Way Berkeley, CA 94704	Site closed, no subjects enrolled
United States	1027	Jason A. Chesney, MD, PhD University of Louisville James Graham Brown Cancer Center 529 South Jackson Street Louisville, KY 40202	Site closed, no subjects enrolled
United States	1028	Vasileios J. Assikis, MD Piedmont Cancer Institute, P.C. 1800 Howell Mill Road, Suite 800 Atlanta, GA 30318	
United States	1030	Nancy A. Dawson, MD Lombardi Comprehensive Cancer Center Georgetown University Hospital 3800 Reservoir Road, NW Washington, DC 20057	Site closed, no subjects enrolled

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
United States	1031	Peter Van Veldhuizen, MD University of Kansas Cancer Center & Medical Pavilion 2330 Shawnee Mission Parkway, Suite 210 Westwood, KS 66205	
Czech Republic	2001	Jiri Tomášek, MD Masarykův onkologický ústav Klinika komplexní onkologické péče Žlutý kopec 543/7 656 53, Brno	
Czech Republic	2002	Vladimira Stáhalová, MD Nemocnice Na Bulovce Ústav radiační onkologie Na Truhlarce 100 180 01, Prague 8	
Czech Republic	2003	Jana Katolická, MD, PhD Fakultní nemocnice u sv. Anny v Brně Onkologicko-chirurgické oddělení Pekařská 53 656 91, Brno	
Czech Republic	2004	Jana Prausová, MD Fakultní nemocnice v Motole Radioterapeuticko - onkologické oddělení V Úvalu 84 150 06, Prague 5	
Czech Republic	2005	Prof. Bohuslav Melichar, MD, PhD Fakultní nemocnice Olomouc Onkologická klinika I. P. Pavlova 6 779 00, Olomouc	
Spain	3001	Jose Pablo Maroto, MD Departamento de Oncologia Medica Hospital de la Santa Creu i Sant Pau Calle Sant Antoni Maria Claret, 167 08025 Barcelona	
Spain	3002	Begona Mellado Gonzalez, MD Hospital Clinic I Provincial C/Villarreal 170 08036 Barcelona	

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
Spain	3003	Ignacio Gil-Bazo, PhD Medical Oncology Department Clinica Universitaria de Navarra Avenida de Pio XII, 36 31008 Pamplona	Site closed, no subjects enrolled
Spain	3004	Daniel Castellano, MD Hospital Universitario 12 de Octubre Avenida de Córdoba s/n 28041 Madrid	
Spain	3005	Maria Jose Mendez Vidal, MD Medical Oncology Department Hospital Reina Sofía Avenida. Menéndez Pidal s/n 14004 Cordoba	
Spain	3006	Jesus Garcia-Donas Jimenez, MD Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal C/ Ona, 10 28050 Madrid	Site closed, no subjects enrolled
Poland	4001	Violetta Sulzyc-Bielicka, MD, PhD Samodzielny Publiczny Szpital Kliniczny nr 2 PUM w Szczecinie Klinika Chirurgii Ogólnej I Onkologicznej ul. Powstancow Wielkopolskich 72 Szczecinie, 70-111	
Poland	4002	Prof. Jacek Jassem, MD, PhD Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radioterapii ul. Debinki 7 Gdansk, 80-952	
Poland	4003	Ewa Kalinka-Warzocho, MD, PhD Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi ul. Pabianicka 62 Lodz, 93-513	
Poland	4004	Jakub Zolnierek, MD Centrum Onkologii Instytut im. Marri Sklodowskiej-Curie Klinika Nowotworow Układu Moczowego ul. Roentgena 5 Warsaw, 02-781	

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
United Kingdom	7001	James Larkin, PhD Royal Marsden Hospital - Fulham 203 Fulham Road London, SW3 6JJ	
United Kingdom	7002	James G. Larkin, MD Royal Marsden Hospital – Downs Downs Road Sutton, SM2 5PT	Site closed, no subjects enrolled
United Kingdom	7003	Richard Wyn Griffiths, PhD Clatterbridge Centre for Oncology Caltterbridge Road Wirral, Bebington, CH63 4JY	
United Kingdom	7004	Dr. Steven Nicholson, PhD, MRCP Leicester Royal Infirmary Infirmary Square Leicester, LE1 5WW	Site closed, no subjects enrolled
United Kingdom	7005	Prof. Robert E. Hawkins Christie Hospital NHS Foundation Trust Department of Medical Oncology Wlmslow Road Manchester, M20 4BX	
United Kingdom	7006	Prof. Timothy Eisen Addenbrooke's Hospital, University of Cambridge Hills Rd Cambridge, CB2 0QQ	
United Kingdom	7007	Agnieszka Michael, PhD Royal Surrey County Hospital, NHS Foundation Trust Egerton Road Guildford, Surrey, GU2 7XX	
United Kingdom	7008	Dr. Ramachandran Venkitaraman The Ipswich Hospital NHS Trust Heath Road Ipswich, IP4 5PD	Site closed, no subjects enrolled
United Kingdom	7009	Matthew Wheeler, PhD Southampton General Hospital Tremona Road Southampton, SO16 6YD	
United Kingdom	7010	Dr. Amit K. Bahl, MD Bristol Haematology and Oncology Centre Horfield Road Bristol, BS2 8ED	

COUNTRY	SITE	PRINCIPAL INVESTIGATOR & STUDY SITE INFORMATION	NOTES
United Kingdom	7011	Hilary Glen, PhD Beatson West of Scotland Cancer Centre 1053 Great Western Road Glasgow, G12 0YN	
United Kingdom	7012	Jason Lester, MD Velindre Cancer Centre Velindre Road Whitchurch, Cardiff, CF14 2TL	
United Kingdom	7014	Dr. Christy Ralph The Leeds Teaching Hospitals NHS Trust St. James Institute of Oncology, St. James University Hospital Beckett Street Leeds, LS9 7TF	
United Kingdom	7015	Dr. Angela Clare Scott Tayside Cancer Centre Ninewells Hospital Dundee, DD1 9SY	

16.1.1 Protocol and Protocol Amendments

The final revised study [protocol](#) incorporating all protocol amendments is provided on the following pages, as are the amendment forms depicting the changes in [Amendment 01](#) through [Amendment 05](#).

REVISION HISTORY

Revisions to Amendment 05 of the protocol (Version 6.0)		
Date: 11 Nov 2014		
Change	Rationale	Affected Protocol Sections
Change in everolimus dose adjustment guidelines for management of non-infectious pneumonitis in subjects receiving everolimus in combination therapy with E7080.	To reflect changes in Afinitor (everolimus) Summary of Product Characteristics (SmPC updated 03 Jun 2014) dose adjustment recommendations. The Afinitor (everolimus) updated SmPC dose adjustment recommendations have been revised, and the latest version of the SmPC dated 03 Jun 2014 contain additional instructions (eg, discontinuing treatment if failure to recover from Grade 2 non-infectious pneumonitis within 4 weeks of re-initiating treatment) that are not detailed in the current dose interruption and reduction instructions of the protocol (Amendment 04 version 27 Jan 2014). Continuing on everolimus beyond the 4 weeks may have safety consequences, hence the requirement to clarify the dose adjustment instructions in the protocol.	Section 8.4.2.4 (Management of Non-infectious Pneumonitis)
Addition of guidance on the management of posterior reversible encephalopathy syndrome (PRES).	To include guidance on the management of PRES in agreement with the Voluntary Harmonisation Procedure.	Section 8.4.2.4
Other administrative changes which do not affect the conduct of study: - Revising for the actual starting dose of everolimus in combination dosing - Referring to prescribing information (without detailing further) for everolimus single agent dosing - Updating sponsor personnel details	Administrative changes	Signature page Section 8.4.2.4 (Management of Non-infectious Pneumonitis)
Revisions to Amendment 04 of the protocol (Version 5.0)		
Date: 27 January 2014		
Change	Rationale	Affected Protocol Sections
To include guidance on management of hepatotoxicity and thromboembolic events	As per the agreement with Voluntary Harmonisation Procedure (VHP).	Synopsis ; Section 8.4.2.4

Revisions to Amendment 03 of the protocol (Version 4.0) Date: 28 February 2013		
Change	Rationale	Affected Protocol Sections
Clarification that Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be used to assess tumor response	The sole modification to RECIST 1.1 is that chest x-rays are not to be used to follow disease	Appendix 1 and throughout
Addition of actual maximum tolerated dose (MTD)/recommended Phase 2 (RP2) dose	To give further information to investigator	Synopsis; Section 8.1; Figure 2; Section 8.2
Extension of window of consent so that informed consent can be signed up to 8 weeks before the first dose of study drug is administered	To allow more flexibility in scheduling screening assessments, particularly those requiring a long time to book in advance	Synopsis; Table 10; Section 8.5.2.1; Section 10.1.3
Subjects are to have evidence of disease progression on or within 9 months of stopping prior therapy, not 6 months	To broaden eligibility	Synopsis; inclusion criterion #5; Section 8.1; Section 8.1.1.1; Section 8.5.2.1
Subjects are to have had one prior disease progression episode on or after vascular endothelial growth factor (VEGF)-targeted treatment	To allow subjects to have had, for example, two prior VEGF-targeted treatments if one of these was given in the adjuvant setting	Synopsis; inclusion criterion #6; exclusion criterion #2; Section 8.5.2.1
Additional wording to inform on dose adjustment for special populations receiving everolimus	To reflect changes in everolimus prescribing information (Jan 2013)	Synopsis; Section 8.4.2.3
To allow bisphosphonates to be administered as prescribed by the treating physician	To remove the restriction against bisphosphonate use as this is not considered to interfere with assessment of the study treatments	Section 8.4.7.2
Addition of hydroxyl diphosphonate or ¹⁸ F Na-F-PET as methods of measuring bone lesions; clarification of use of computerized tomography scans and use of magnetic resonance imaging	To clarify method of measuring lesions	Section 8.5.1.4; Table 10; Table 11
The 12 hour pharmacokinetic (PK) sampling time point has been made optional, and the intensive PK sampling will become mandatory if an insufficient number of subjects enter voluntarily.	The 12 hour sampling time point has led to an insufficient number of subjects participating in the optional intensive PK substudy. Because of the importance of collecting PK samples, the intensive PK sampling will become mandatory if an insufficient number of subjects enter voluntarily.	Section 8.5.1.5; Table 7; Table 10; Section 8.5.2.2
Vital sign measurements changed from supine to resting	To allow easier measurement at site	Table 10; Table 11
“Elevated BP” is defined and the instructions for blood pressure monitoring are given more detail	To add clarity	Table 10; Table 11

Clarification of need for proteinuria measurements	Subjects negative for or with trace/1+ proteinuria for 3 consecutive months need not have further evaluation for proteinuria, but they must return for proteinuria measurement if they experience a further event of proteinuria $\geq$ Grade 2	Section 8.4.2.4, Table 10; Section 8.5.2.2; Table 11; Section 8.5.2.3
Clarification that urinalysis is to take place at the site	To allow easier measurement at the site	Table 10; Table 11
Definition of end of study added	For all studies conducted in the EU, it is necessary to include a definition of end of study for the purpose of public disclosure of the clinical study results.	Section 10.1.1
Revisions to Amendment 02 of the protocol (Version 3.0) Date: 09 Jul 2012		
Change	Rationale	Affected Protocol Sections
Addition of IND and EudraCT numbers	Requirement per current protocol template	Title page
Addition of protocol revision history table	Requirement per current protocol template	Page following Title page
Change in dose reduction and interruption instructions for subjects who experience E7080-everolimus combination therapy-related toxicity and single agent E7080-related toxicity.	Improved safety	- Synopsis – Study Treatments and Table B - Section 8.4.2.3 and Table 3
Revisions to Amendment 01 of the protocol (Version 2.0) Date: 14 Mar 2011		
Change	Rationale	Affected Protocol Sections
Change in sponsor personnel	Administrative change	Signature page
Change in Inclusion Criteria with regard to subjects who will be treated with Afinitor (everolimus)	For CTA submissions in Europe, Phase 1b subjects required to have disease progression after prior VEGF-targeted treatment in accordance with marketing authorization label for Afinitor (everolimus)	- Synopsis (Inclusion Criterion #2) - Section 8.3.1 (Inclusion Criterion #2)
Change in Inclusion Criteria with regard to contraceptive use in subjects	For CTA submissions in Europe, revised wording to reflect the UK regulatory guidelines for contraception when drugs used in clinical trials are known to be teratogenic	- Synopsis (Inclusion Criteria #15 and 16) - Section 8.3.1 (Inclusion Criteria #15 and 16)

Change in dose reduction and interruption instructions for subjects who experience E7080-everolimus combination therapy related toxicity and single agent E7080-related toxicity for subjects with tolerable Grade 2 toxicities	Revised wording to include previously omitted instructions for tolerable Grade 2 toxicities	• Synopsis – Study Treatments and Table B • Section 9.8.4.2.3 and Table 3
Typographical and other minor wording errors	Changed for accuracy	As needed throughout document